Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes
BackgroundMyelodysplastic syndromes (MDSs) are a very heterogeneous group of myeloid disorders with high prevalence and risk of developing acute myeloid leukemia. The more accurate risk stratification can provide a better guidance of treatment. The platelet–large cell ratio (P-LCR) is a parameter re...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.846044/full |
| _version_ | 1818393433948028928 |
|---|---|
| author | Qiuni Chen Qiuni Chen Yue Chen Yue Chen Yijing Zhang Yijing Zhang Lijuan Zhang Lijuan Zhang Kankan Chen Kankan Chen Zhengmei He Zhengmei He Chunling Wang Chunling Wang Liang Yu Liang Yu |
| author_facet | Qiuni Chen Qiuni Chen Yue Chen Yue Chen Yijing Zhang Yijing Zhang Lijuan Zhang Lijuan Zhang Kankan Chen Kankan Chen Zhengmei He Zhengmei He Chunling Wang Chunling Wang Liang Yu Liang Yu |
| author_sort | Qiuni Chen |
| collection | DOAJ |
| description | BackgroundMyelodysplastic syndromes (MDSs) are a very heterogeneous group of myeloid disorders with high prevalence and risk of developing acute myeloid leukemia. The more accurate risk stratification can provide a better guidance of treatment. The platelet–large cell ratio (P-LCR) is a parameter reported in complete blood cell count tests, and was associated with many diseases, but its role in MDS is not clear.PurposeThis study aims to explore the impact of the P-LCR on the prognosis of patients with MDS, which is of great significance for clinical treatment.MethodsIn the retrospective study, 122 newly diagnosed MDS patients were enrolled. We used the bioinformatics tool X-tile to define a P-LCR threshold of 36.7% to predict prognosis. Patients were divided into P-LCRlow and P-LCRhigh groups, and their characteristics were compared between the two groups.ResultsResults show that the P-LCRlow was associated with worse overall survival (OS) than the P-LCRhigh patients (median OS, 18.53 months versus 25.77 months, p=0.0057), but there were no statistical differences in progression-free survival (PFS) between the two groups (p=0.2001). The results of univariate and multivariate Cox proportional hazard analyses adjusted for gender, bone marrow blast level, platelet count, and International Prognostic Scoring System scores showed that the P-LCR was useful in the evaluation of PFS [hazard ratio (HR) 0.212, 95%CI 0.064–0.702, p=0.011] and OS of MDS (HR 0.464, 95%CI 0.284–0.757, p=0.002).ConclusionThis study is the first report showing that the P-LCR would be a simple and immediately available biomarker for predicting the prognosis of MDS. |
| first_indexed | 2024-12-14T05:45:15Z |
| format | Article |
| id | doaj.art-cae27682edea416ab0c9e2d13431f9f0 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-14T05:45:15Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-cae27682edea416ab0c9e2d13431f9f02022-12-21T23:14:54ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-04-011210.3389/fonc.2022.846044846044Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic SyndromesQiuni Chen0Qiuni Chen1Yue Chen2Yue Chen3Yijing Zhang4Yijing Zhang5Lijuan Zhang6Lijuan Zhang7Kankan Chen8Kankan Chen9Zhengmei He10Zhengmei He11Chunling Wang12Chunling Wang13Liang Yu14Liang Yu15Department of Hematology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian, ChinaKey Laboratory of Hematology of Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian, ChinaKey Laboratory of Hematology of Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian, ChinaKey Laboratory of Hematology of Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian, ChinaKey Laboratory of Hematology of Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian, ChinaKey Laboratory of Hematology of Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian, ChinaKey Laboratory of Hematology of Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian, ChinaKey Laboratory of Hematology of Nanjing Medical University, Nanjing, ChinaDepartment of Hematology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian, ChinaKey Laboratory of Hematology of Nanjing Medical University, Nanjing, ChinaBackgroundMyelodysplastic syndromes (MDSs) are a very heterogeneous group of myeloid disorders with high prevalence and risk of developing acute myeloid leukemia. The more accurate risk stratification can provide a better guidance of treatment. The platelet–large cell ratio (P-LCR) is a parameter reported in complete blood cell count tests, and was associated with many diseases, but its role in MDS is not clear.PurposeThis study aims to explore the impact of the P-LCR on the prognosis of patients with MDS, which is of great significance for clinical treatment.MethodsIn the retrospective study, 122 newly diagnosed MDS patients were enrolled. We used the bioinformatics tool X-tile to define a P-LCR threshold of 36.7% to predict prognosis. Patients were divided into P-LCRlow and P-LCRhigh groups, and their characteristics were compared between the two groups.ResultsResults show that the P-LCRlow was associated with worse overall survival (OS) than the P-LCRhigh patients (median OS, 18.53 months versus 25.77 months, p=0.0057), but there were no statistical differences in progression-free survival (PFS) between the two groups (p=0.2001). The results of univariate and multivariate Cox proportional hazard analyses adjusted for gender, bone marrow blast level, platelet count, and International Prognostic Scoring System scores showed that the P-LCR was useful in the evaluation of PFS [hazard ratio (HR) 0.212, 95%CI 0.064–0.702, p=0.011] and OS of MDS (HR 0.464, 95%CI 0.284–0.757, p=0.002).ConclusionThis study is the first report showing that the P-LCR would be a simple and immediately available biomarker for predicting the prognosis of MDS.https://www.frontiersin.org/articles/10.3389/fonc.2022.846044/fullmyelodysplastic syndromes (MDS)platelet–large cell ratio (P-LCR)survivalprognosisbiomarker |
| spellingShingle | Qiuni Chen Qiuni Chen Yue Chen Yue Chen Yijing Zhang Yijing Zhang Lijuan Zhang Lijuan Zhang Kankan Chen Kankan Chen Zhengmei He Zhengmei He Chunling Wang Chunling Wang Liang Yu Liang Yu Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes Frontiers in Oncology myelodysplastic syndromes (MDS) platelet–large cell ratio (P-LCR) survival prognosis biomarker |
| title | Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes |
| title_full | Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes |
| title_fullStr | Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes |
| title_full_unstemmed | Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes |
| title_short | Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes |
| title_sort | prognostic impact of platelet large cell ratio in myelodysplastic syndromes |
| topic | myelodysplastic syndromes (MDS) platelet–large cell ratio (P-LCR) survival prognosis biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.846044/full |
| work_keys_str_mv | AT qiunichen prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT qiunichen prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT yuechen prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT yuechen prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT yijingzhang prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT yijingzhang prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT lijuanzhang prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT lijuanzhang prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT kankanchen prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT kankanchen prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT zhengmeihe prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT zhengmeihe prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT chunlingwang prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT chunlingwang prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT liangyu prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes AT liangyu prognosticimpactofplateletlargecellratioinmyelodysplasticsyndromes |